Differences in drug use between men and women: an Italian cross sectional study

Abstract

BackgroundDrugs are the most important treatment option for most diseases, and the majority of medical consultations result in a prescription. Women and men receive different drug prescriptions and differ in therapeutic response to pharmacological therapy. This disparity is due to biological factors (sex differences) or/and behavior, lifestyle and life experience (gender differences). Sex differences in drug use have been demonstrated in several therapeutic areas; however, there is a lack of overviews on sex and gender differences of drug use in an entire population.MethodsWe conducted a descriptive cross - sectional drug use study, involving the entire Italian population in 2012, aimed at showing and analyzing differences between men and women as regards their exposure to drugs. The data source was IMS LifeLink Treatment DynamicsTMLRx Database and it included all prescribed drugs reimbursed by the Italian National Healthcare System in 2012 and covered 90% of the entire Italian population.The information about the prescriptions was stratified by men and women and age. Drug consumption was expressed as DDD/ 1000 ab die. Exposure to drug prescriptions was expressed as period prevalence (the proportion of the population dispensed ≥1 prescription in 2012 per 1000 inhabitants). Differences of prevalence between men and women were expressed as crude and age adjusted risk ratios with 95% CI.ResultsOur findings suggested that the largest differences in drug prescriptions regarded drugs affecting bone structure and mineralization (RR 15.9), calcium (RR 8.6) and thyroid therapy (RR 5.4), dispensed more to women than men. Otherwise ACE inhibitors were more commonly used in men.ConclusionsThis is the first study exploring difference in drug use between men and women and carried out on the entire Italian population. Our findings showed substantial differences between men and women in term of prevalence of drug prescriptions. Some differences in drug use may be explained by sex differences (variations in disease prevalence and severity, pathophysiology, or by other biological differences), other differences need further investigation to explain the apparent lack of a rational medical explanation for some findings.The findings may subsequently be used to plan future studies to address differences suggesting inequity in treatment approaches.Electronic supplementary materialThe online version of this article doi:(10.1186/s12905-017-0424-9) contains supplementary material, which is available to authorized users.

<p>Drug Utilization Pattern of Antibiotics: The Role of Age, Sex and Municipalities in Determining Variation</p>

“…The above databases had been previously validated and used to produce drug-utilization information. [20][21][22][23][24][25] Data sources were matched by record linkage analysis through a unique and anonymous personal identification code. Such code was created by a database manager uninvolved in the data analysis, preventing patient identification.…”

New Nanotechnologies for the Treatment and Repair of Skin Burns Infections

“…The European Medicines Agency (EMA) may be open to new authorizations because clinical trials with nanomedicines have being increasing in Europe in the last decades. Studies on follow up, use, compliance, and assessment in this area are nevertheless still needed [14][15][16][17]. Regenerative medicine is one of the branches of nanomedicine that is most promising for the approval of new medicines and therapies [10].…”

Multiple Cell Signalling Pathways of Human Proinsulin C-Peptide in Vasculopathy Protection

“…Alternative therapeutic approaches to hyperglycemic control are necessary to target hyperglycemia and diabetic complications. In this field, several clinical and experimental studies demonstrated that C-peptide treatment, alone and/or also in combination with insulin, has aphysiological functions, being beneficial in the prevention diabetic complications; studies on follow up, use, and compliance, as reported by recent publications in the area [134][135][136][137] and communication strategies and assessment [138] are nevertheless still needed. A summary of the cytoprotective, antiapoptotic and anti-inflammatory effects of C-peptide, on the renal function and on diabetic neuropathy is provided in Table 1.…”